Table 3.

Odds ratios for breast cancer and total PCBs in relation to CYP1A1 M3 genotypes in African American women

Total PCBsa	CYP1A1 M3 genotype	All participants		Premenopausal		Postmenopausal
		Patients/controls	OR (95% CI)b	Patients/controls	OR (95% CI)b	Patients/controls	OR (95% CI)b
<0.430	Non-M3	95/95	Referent	73/70	Referent	22/25	Referent
≥0.430	Non-M3	105/100	1.3 (0.8–2.0)	31/24	1.6 (0.8–3.2)	74/76	1.0 (0.5–2.0)
<0.430	Any M3	13/26	0.6 (0.3–1.2)	8/14	0.7 (0.3–1.7)	5/12	0.5 (0.2–1.6)
≥0.430	Any M3	29/21	1.6 (0.8–3.2)	7/6	1.5 (0.5–4.7)	22/15	1.5 (0.6–3.6)
ICR (95% CI)			0.8 (-0.3,1.9)		0.2 (-1.7,2.1)		1.0 (-0.2,2.1)

^aLipid-adjusted total imputed PCBs (ng/ml).

^bOdds ratios adjusted for age and sampling fractions.

Any M1, M1/M1 or M1/non-M1; CI, confidence interval; ICR, interaction contrast ratio; non-M1, non-M1/non-M1.